Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Market Cap	17.92B
Revenue (ttm)	2.83B
Net Income (ttm)	608.27M
Shares Out	66.57M
EPS (ttm)	9.06
PE Ratio	29.71
Forward PE	n/a
Dividend	2.50 (0.90%)
Ex-Dividend Date	Sep 12, 2025

Volume	223,388
Average Volume	811,761
Open	275.45
Previous Close	278.35
Day's Range	267.55 - 281.70
52-Week Range	139.90 - 328.04
Beta	0.24
RSI	55.74
Earnings Date	Aug 6, 2025

About Theseus Pharmaceuticals

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in New Delhi, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 1,025
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: JAGSNPHARM

Financial Performance

In 2024, Jagsonpal Pharmaceuticals's revenue was 2.69 billion, an increase of 28.76% compared to the previous year's 2.09 billion. Earnings were 553.61 million, an increase of 146.45%.